and development of
new antibiotics and
The Netherlands Antibiotic Development Platform
The Netherlands Antibiotic Development Platform (NADP) facilitates the collaboration between public and private organisations, to enhance the development of new antibiotics and alternative therapies for infectious diseases in humans and animals.
NADP will identify relevant research groups, institutes and companies involved in chemical, biological, and/or biomedical antibiotic research to forge collaborations through targeted connections and will organise regular meetings with interested parties.
Stay informed on NADP and subscribe to our Update.
An important objective of NADP is to increase R&D productivity related to new antibiotics and alternatives. To promote the accelerated development of promising 'leads', NADP has developed a financing instrument specifically for this purpose: the NADP Vouchers.
These vouchers can be used in various phases of drug development to gain advice and intensive supervision of research projects from independent consultants or CROs that have specific knowledge and expertise pertinent to the pharmaceutical development process and clinical applications.
The AMR Action Fund has announced its first investment to fulfill its aim to bring two to four new antibiotics to market. The fund will provide for research in Adaptive Phagte Therapeutics (APT) and Venatorx Pharmaceuticals.
The third AMR Benchmark is an independent report that compares and analyses how pharmaceutical companies are responding to the crisis of antimicrobial resistance.
This World Antimicrobial awareness week, GARDP, together with WHO, will be holding an AMR Discussions webinar. A panel will discuss the roles that different actors can play in the development of new antibiotics.